PURPOSE: Inhibitors of the mammalian target of rapamycin (mTOR) kinase have shown clinical activity in several lymphoma subtypes. Sirolimus, an mTOR inhibitor, also has activity in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT). We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression. PATIENTS AND METHODS: We retrospectively analyzed 190 patients who underwent transplantation for lymphoma. We compared the outcomes of patients who received sirolimus for GVHD prophylaxis with those of patients who received transplantation with a combination of a calcineurin inhibitor and methotrexate without sirolimus. RESULTS: Overall survival (OS) after transplantation was significantly superior in the sirolimus group, which was confirmed in multivariable analysis. The benefit was restricted to patients undergoing reduced-intensity conditioning (RIC) HSCT (3-year OS, 66% for sirolimus group v 38% for no-sirolimus group; P = .007; hazard ratio [HR] for mortality in multivariable analysis = 0.5, P = .042). Patients who received sirolimus had a similar incidence of nonrelapse mortality but a decreased incidence of disease progression compared with patients who did not receive sirolimus (3-year cumulative incidence of progression, 42% v 74%, respectively; P < .001; HR for progression in multivariable analysis = 0.4, P = .01). The effect of sirolimus persisted after adjusting for the occurrence of GVHD. No such survival advantage was apparent in a similar comparison of patients who underwent transplantation for diseases other than lymphoma. CONCLUSION: This study suggests that sirolimus can independently decrease the risk of lymphoma progression after RIC HSCT, paving the way for prospective clinical trials.
PURPOSE: Inhibitors of the mammalian target of rapamycin (mTOR) kinase have shown clinical activity in several lymphoma subtypes. Sirolimus, an mTOR inhibitor, also has activity in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT). We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression. PATIENTS AND METHODS: We retrospectively analyzed 190 patients who underwent transplantation for lymphoma. We compared the outcomes of patients who received sirolimus for GVHD prophylaxis with those of patients who received transplantation with a combination of a calcineurin inhibitor and methotrexate without sirolimus. RESULTS: Overall survival (OS) after transplantation was significantly superior in the sirolimus group, which was confirmed in multivariable analysis. The benefit was restricted to patients undergoing reduced-intensity conditioning (RIC) HSCT (3-year OS, 66% for sirolimus group v 38% for no-sirolimus group; P = .007; hazard ratio [HR] for mortality in multivariable analysis = 0.5, P = .042). Patients who received sirolimus had a similar incidence of nonrelapse mortality but a decreased incidence of disease progression compared with patients who did not receive sirolimus (3-year cumulative incidence of progression, 42% v 74%, respectively; P < .001; HR for progression in multivariable analysis = 0.4, P = .01). The effect of sirolimus persisted after adjusting for the occurrence of GVHD. No such survival advantage was apparent in a similar comparison of patients who underwent transplantation for diseases other than lymphoma. CONCLUSION: This study suggests that sirolimus can independently decrease the risk of lymphoma progression after RIC HSCT, paving the way for prospective clinical trials.
Authors: David T Teachey; Dana A Obzut; Jonathan Cooperman; Junjie Fang; Martin Carroll; John K Choi; Peter J Houghton; Valerie I Brown; Stephan A Grupp Journal: Blood Date: 2005-09-29 Impact factor: 22.113
Authors: Corey Cutler; Shuli Li; Vincent T Ho; John Koreth; Edwin Alyea; Robert J Soiffer; Joseph H Antin Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: A Mehrabi; H Fonouni; A Kashfi; B M Schmied; Ch Morath; M Sadeghi; P Schemmer; J Encke; P Sauer; M Zeier; J Weitz; M W Büchler; J Schmidt Journal: Clin Transplant Date: 2006 Impact factor: 2.863
Authors: Sang-Hoon Sin; Debasmita Roy; Ling Wang; Michelle R Staudt; Farnaz D Fakhari; Dhavalkumar D Patel; David Henry; William J Harrington; Blossom A Damania; Dirk P Dittmer Journal: Blood Date: 2006-11-02 Impact factor: 22.113
Authors: Maria Vaysberg; Cynthia E Balatoni; Ronald R Nepomuceno; Sheri M Krams; Olivia M Martinez Journal: Transplantation Date: 2007-04-27 Impact factor: 4.939
Authors: Manuel Jurado; Carlos Vallejo; José A Pérez-Simón; Salut Brunet; Christelle Ferra; Pascual Balsalobre; Jaime Pérez-Oteyza; Ildefonso Espigado; Antonio Romero; Dolores Caballero; Jorge Sierra; Jose M Ribera; Jose L Díez Journal: Biol Blood Marrow Transplant Date: 2007-06 Impact factor: 5.742
Authors: Shoba Amarnath; Francis A Flomerfelt; Carliann M Costanzo; Jason E Foley; Jacopo Mariotti; Daniel M Konecki; Anu Gangopadhyay; Michael Eckhaus; Susan Wong; Bruce L Levine; Carl H June; Daniel H Fowler Journal: Autophagy Date: 2010-05-16 Impact factor: 16.016
Authors: Vincent T Ho; Haesook T Kim; Julie Aldridge; Deborah Liney; Grace Kao; Philippe Armand; John Koreth; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea Journal: Biol Blood Marrow Transplant Date: 2010-12-27 Impact factor: 5.742
Authors: Kevin R Kelly; Julie H Rowe; Swaminathan Padmanabhan; Steffan T Nawrocki; Jennifer S Carew Journal: Target Oncol Date: 2011-04-17 Impact factor: 4.493
Authors: Joseph Pidala; Jongphil Kim; Melissa Alsina; Ernesto Ayala; Brian C Betts; Hugo F Fernandez; Teresa Field; Heather Jim; Mohamed A Kharfan-Dabaja; Frederick L Locke; Asmita Mishra; Taiga Nishihori; Leonel Ochoa-Bayona; Lia Perez; Marcie Riches; Claudio Anasetti Journal: Haematologica Date: 2015-04-03 Impact factor: 9.941